68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

Summary

This phase I trial studies the side effects of 68GA-PSMA-11 PET imaging in patients with prostate cancer that has come back (recurrent). Gallium (68Ga) is a radiotracer that binds to a molecule, PSMA, that is found in abundance on most prostate cancer cells. PSMA is short for 'prostate specific membrane antigen'. Diagnostic procedures, such as 68GA-PSMA-11 PET imaging, may help measure a patient's response to earlier treatment, and may help plan the best treatment for prostate cancer.

Timeline

Start

2019-12-12

Primary completion

2022-12-09

Completion

2022-12-09

Drugs

Indications